REMARKS

Claims 1-15 are pending in this application. The claims have been amended only in formal respects to place them in condition for examination in the U.S. national stage of the international application. None of the amendments narrow the scope of any claims.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: October 1, 2004

Steven J. Scot

Reg. No. 43,911

Abstract

A method for the treatment of symptoms of disorders and conditions with sensorimotor gating deficits with an alpha2-adrenoceptor antagonist, or its pharmaceutically acceptable ester or salt thereof, being selective for the alpha2C-adrenoceptor subtype.